JP2017532577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532577A5 JP2017532577A5 JP2017529971A JP2017529971A JP2017532577A5 JP 2017532577 A5 JP2017532577 A5 JP 2017532577A5 JP 2017529971 A JP2017529971 A JP 2017529971A JP 2017529971 A JP2017529971 A JP 2017529971A JP 2017532577 A5 JP2017532577 A5 JP 2017532577A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- cyfra
- crp
- ferritin
- cea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000008416 Ferritin Methods 0.000 claims 25
- 108010074051 C-Reactive Protein Proteins 0.000 claims 22
- 102100032752 C-reactive protein Human genes 0.000 claims 22
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 22
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 22
- 102000008857 Ferritin Human genes 0.000 claims 21
- 108050000784 Ferritin Proteins 0.000 claims 21
- 238000000034 method Methods 0.000 claims 18
- 238000001514 detection method Methods 0.000 claims 16
- 206010009944 Colon cancer Diseases 0.000 claims 14
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 14
- 239000012472 biological sample Substances 0.000 claims 13
- 239000000523 sample Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- -1 CYFRA Proteins 0.000 claims 7
- 102100024940 Cathepsin K Human genes 0.000 claims 6
- 102100022133 Complement C3 Human genes 0.000 claims 6
- 108010001517 Galectin 3 Proteins 0.000 claims 6
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 claims 6
- 101000910979 Homo sapiens Cathepsin Z Proteins 0.000 claims 6
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 6
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 6
- 208000003200 Adenoma Diseases 0.000 claims 5
- 239000000090 biomarker Substances 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 206010001233 Adenoma benign Diseases 0.000 claims 4
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 4
- 108010028780 Complement C3 Proteins 0.000 claims 3
- 102000000802 Galectin 3 Human genes 0.000 claims 3
- 102100039558 Galectin-3 Human genes 0.000 claims 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 3
- 108091005995 glycated hemoglobin Proteins 0.000 claims 3
- 229960005356 urokinase Drugs 0.000 claims 3
- 102000012060 Septin 9 Human genes 0.000 claims 2
- 108050002584 Septin 9 Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 238000011269 treatment regimen Methods 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 claims 1
- 108010066302 Keratin-19 Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000002052 colonoscopy Methods 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000002579 sigmoidoscopy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040874P | 2014-08-22 | 2014-08-22 | |
| US62/040,874 | 2014-08-22 | ||
| PCT/US2015/046301 WO2016029117A1 (en) | 2014-08-22 | 2015-08-21 | Methods for the early detection of colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532577A JP2017532577A (ja) | 2017-11-02 |
| JP2017532577A5 true JP2017532577A5 (enExample) | 2018-10-04 |
| JP6750140B2 JP6750140B2 (ja) | 2020-09-02 |
Family
ID=54035324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529971A Expired - Fee Related JP6750140B2 (ja) | 2014-08-22 | 2015-08-21 | 直腸結腸がんを早期検出するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160178631A1 (enExample) |
| EP (1) | EP3183578B8 (enExample) |
| JP (1) | JP6750140B2 (enExample) |
| CN (1) | CN107110865B (enExample) |
| ES (1) | ES2813829T3 (enExample) |
| WO (1) | WO2016029117A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020091408A1 (ko) * | 2018-10-30 | 2020-05-07 | 주식회사 애니벳 | 반려동물에서 종양질병의 보조적 진단을 위한 바이오마커 검사방법 |
| KR102407703B1 (ko) * | 2018-10-30 | 2022-06-22 | 바디텍메드(주) | 반려동물의 종양 질병을 보조적으로 진단하는 바이오마커 검사방법 |
| CN109557311B (zh) * | 2018-12-13 | 2022-02-15 | 中南大学湘雅医院 | 结直肠癌诊断标志物及结直肠癌的检测产品及其应用 |
| WO2021024009A1 (en) * | 2019-08-02 | 2021-02-11 | Shanghai Yunxiang Medical Technology Co., Ltd. | Methods and compositions for providing colon cancer assessment using protein biomarkers |
| JP7741067B2 (ja) * | 2019-10-18 | 2025-09-17 | エグザクト サイエンシーズ コーポレーション | 複数の分析物を用いた糞便抗原検査 |
| CN113018416B (zh) * | 2021-03-09 | 2022-09-20 | 复旦大学附属中山医院 | 天冬酰胺内肽酶抑制剂的制药用途 |
| CN118197643B (zh) * | 2024-04-03 | 2025-01-07 | 南通大学附属医院 | 基于肠道环境数据的肠道肿瘤检测系统 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060154245A1 (en) * | 1999-04-09 | 2006-07-13 | Rigshospitalet | Method for detecting, screening and/or montoring a cancer in individual |
| JP2004198419A (ja) * | 2002-12-13 | 2004-07-15 | Bayer Healthcare Llc | Ｔｉｍｐ１を用いた検出方法 |
| EP1761781A1 (en) * | 2004-06-18 | 2007-03-14 | Roche Diagnostics GmbH | Use of protein rs15a as a marker for colorectal cancer |
| JP4916441B2 (ja) * | 2004-08-13 | 2012-04-11 | インディヴュームド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 結腸直腸腺腫及び／又は癌腫に対するバイオマーカーとしてのトランスサイレチンの使用；検出方法及び試験システム |
| EP1831695B1 (en) * | 2004-12-23 | 2009-05-06 | F. Hoffmann-La Roche AG | Use of cyfra 21-1 and osteopontin as markers for colorectal cancer |
| CN101238373A (zh) * | 2005-08-19 | 2008-08-06 | 因迪维姆德有限公司 | 内质蛋白片段及其衍生物作为结肠直肠腺瘤和/或癌的生物标记的用途；用于检测的方法和测试系统 |
| CN101346628A (zh) * | 2005-12-22 | 2009-01-14 | 霍夫曼-拉罗奇有限公司 | 包含骨桥蛋白和癌胚抗原的标记物组合在结肠直肠癌的评估中的用途 |
| EP2071337A1 (en) * | 2007-12-10 | 2009-06-17 | F.Hoffmann-La Roche Ag | Seprase as a marker for cancer |
| WO2009074276A2 (en) * | 2007-12-10 | 2009-06-18 | Roche Diagnostics Gmbh | Marker panel for colorectal cancer |
| JP5172020B2 (ja) * | 2008-11-12 | 2013-03-27 | エフ．ホフマン−ラ ロシュ アーゲー | 癌のマーカーとしてのｐａｃａｐ |
| US10815517B2 (en) * | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
| JP5312684B2 (ja) * | 2009-05-04 | 2013-10-09 | エフ．ホフマン−ラ ロシュ アーゲー | 癌のマーカーとしてのｄｐｐｉｖ／セプラーゼの使用 |
| BR112012025593A2 (pt) * | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| CN103080334B (zh) * | 2010-06-04 | 2016-05-04 | 复旦大学 | 用于诊断早期结直肠癌及高级腺瘤的微rna生物标记及方法 |
| WO2011158667A1 (ja) * | 2010-06-16 | 2011-12-22 | 国立大学法人浜松医科大学 | 大腸腫瘍の検出方法 |
| EP2678448A4 (en) * | 2011-02-22 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS |
| JP5805518B2 (ja) * | 2011-12-21 | 2015-11-04 | 株式会社島津製作所 | マルチプレックス大腸がんマーカーパネル |
| KR101461615B1 (ko) * | 2012-01-03 | 2015-04-22 | 국립암센터 | 암 진단 장치 |
-
2015
- 2015-08-21 EP EP15757396.5A patent/EP3183578B8/en active Active
- 2015-08-21 US US14/832,441 patent/US20160178631A1/en not_active Abandoned
- 2015-08-21 WO PCT/US2015/046301 patent/WO2016029117A1/en not_active Ceased
- 2015-08-21 JP JP2017529971A patent/JP6750140B2/ja not_active Expired - Fee Related
- 2015-08-21 CN CN201580044032.4A patent/CN107110865B/zh not_active Expired - Fee Related
- 2015-08-21 ES ES15757396T patent/ES2813829T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532577A5 (enExample) | ||
| JP2017518366A5 (enExample) | ||
| EP3349011B1 (en) | Liver cancer test method | |
| JP6386995B2 (ja) | 大腸がんの検出方法 | |
| JP2017524725A5 (enExample) | ||
| JP2013544354A (ja) | 葉酸受容体アルファ発現癌の診断および予後マーカーとしての葉酸受容体アルファ | |
| JP2016500659A5 (enExample) | ||
| Bagchi et al. | Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: a case control study | |
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| CA3220947A1 (en) | Antibody combination against regenerating islet-derived protein 1? and detection kit comprising same | |
| CN110687283A (zh) | 自身抗体在诊断和/或治疗肿瘤中的应用 | |
| EP2548028A1 (en) | Flc as biomarker | |
| Page et al. | Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example | |
| CN110687282A (zh) | PD-1和/或p53自身抗体作为肿瘤疗效预测或预后评估的标志物 | |
| JP7315968B2 (ja) | 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法 | |
| Pu et al. | Development of a chemiluminescence immunoassay for serum YB-1 and its clinical application as a potential diagnostic marker for hepatocellular carcinoma | |
| US11242408B2 (en) | Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis | |
| US10288618B2 (en) | Diagnosis of cancer by detecting dimeric IL-18 | |
| JP2018520366A5 (enExample) | ||
| JP6472457B2 (ja) | 悪性腫瘍性疾患を検出するための組成物および方法 | |
| JP7315965B2 (ja) | ウィルス性肝癌の検出方法 | |
| JP5818817B2 (ja) | がん予後診断アッセイ | |
| JP5221825B1 (ja) | 肺扁平上皮癌の検出方法 | |
| EP3420356B1 (en) | Improved assay | |
| JP2012504408A5 (enExample) |